摘要
目的探讨对妇女绝经后更年期综合征采用坤泰胶囊联合替勃龙治疗的临床效果。方法选择2021年1月—2022年2月丹阳市妇幼保健院收治的绝经后更年期综合征者76例,随机分为对照组(应用替勃龙治疗)与观察组(联用坤泰胶囊治疗),各38例。比较两组临床疗效,检测治疗前后雌二醇(E2)、黄体生成素(LH)、卵泡刺激素(FSH)评估激素分泌状态,检测治疗前后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)指标,并统计不良反应情况。结果观察组总有效率较对照组高(94.74%vs 76.32%),差异有统计学意义(χ^(2)=5.208,P<0.05)。治疗后,观察组E2(78.53±16.22)pmol/L高于对照组,LH(16.86±4.74)IU/L、FHS(37.46±10.10)IU/L小于对照组,差异有统计学意义(t=2.746、2.048、3.161,P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平为(69.55±8.73)%、(44.12±6.25)%、(1.81±0.34)均大于对照组,差异有统计学意义(t=4.169、5.317、3.037,P<0.05)。两组不良反应发生率对比(5.26%vs 7.89%),差异无统计学意义(χ2=0.000,P>0.05)。结论对绝经后更年期综合征患者予坤泰胶囊联合替勃龙治疗疗效可靠,能改善激素分泌状态以及免疫功能,且用药安全性高。
Objective To investigate the clinical effects of treatment with Kuntai capsules combined with tibolone in women with postmenopausal menopausal syndrome.Methods A total of 76 patients with postmenopausal syndrome admitted to Danyang Maternal and Child Health Hospital from January 2021 to February 2022 were selected and randomly divided into control group(treated with tibolone)and observation group(treated with Kuntai capsule),38 cases in each group.Estradiol(E2),luteinizing hormone(LH),follicle stimulating hormone(FSH)were detected before and after treatment to evaluate the hormone secretion status,CD3^(+),CD4^(+),CD4^(+)/CD8^(+)indicators before and after treatment,and the adverse reactions were counted.Results The total effective rate of observation group was higher than that of control group(94.74%vs 76.32%),and the difference was statistically significant(χ^(2)=5.208,P<0.05).After treatment,E2 in the observation group was(78.53±16.22)pmol/L,higher than that in the control group,LH(16.86±4.74)IU/L and FHS(37.46±10.10)IU/L were lower than those in the control group,and the differences were statistically significant(t=2.746,2.048,3.161,P<0.05).After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the observation group were(69.55±8.73)%,(44.12±6.25)%,(1.81±0.34),which were higher than those in the control group,and the differences were statistically significant(t=4.169,5.317,3.037,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(5.26%vs 7.89%)(χ^(2)=0.000,P>0.05).Conclusion The treatment of postmenopausal menopausal syndrome with Kuntai capsule combined with tibolone is reliable,improves hormonal secretion status and immune function,and has high safety of administration.
作者
孔林花
KONG Linhua(Department of Women's Health,Danyang Maternal and Child Health Hospital,Danyang,Jiangsu Province,212300 China)
出处
《世界复合医学》
2022年第10期83-86,共4页
World Journal of Complex Medicine
